IMR Press / EJGO / Volume 34 / Issue 6 / pii/1630906513955-2003882995

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer
X. Xu1,2,†H. Dai3,†Y. Zhao2,4Y. Wang5X. Xu2,5Z. Qian1,2X. Chen2,4,6,*
Show Less
1 Department of Chemotherapy, Jiangsu Institute of Cancer Research, Nanjing
2 Nanjing Medical University, Nanjing
3 Medical School of Yangzhou University, Yangzhou
4 Department of Gynecology Oncology, Jiangsu Institute of Cancer Research, Nanjing
5 Department of Pathology, Jiangsu Hospital of Integrated Traditional and Western Medicine, Nanjing
6 Department of Pathology, Jiangsu Institute of Cancer Research, Nanjing
7 State Key Laboratory of Bioelectronics, South University, Nanjing (China)
These authors contributed equally.
Eur. J. Gynaecol. Oncol. 2013, 34(6), 559–564;
Published: 10 December 2013

Objective: This study aimed to investigate the predictive value of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for chemosensitivity test in ascites. Materials and Methods: The relationship of the in vitro sensitivity results and the clinicopathological characteristics, objective response rates (ORRs) of chemotherapy, and time to progression (TTP) were retrospectively analyzed in 120 epithelial ovarian cancer (EOC) patients. The clinical response criterion was based on the Response Evaluation Criteria in Solid Tumors (RECIST) standard. The log-rank test and Kaplan-Meier curve were used to estimate TTP. Results: MTT assays revealed that tumor cells from ascites of primary and type II EOC were more sensitive to paclitaxel (PTX) and carboplatin (CBDCA) than relapse (p = 0.01 and p < 0.01, respectively) and type I (p = 0.03, p = >0.02, respectively) EOC. p53 positive expression and Ki67 high expression were associated with high PTX (p = 0.01 and p < 0.01, respectively) and CBDCA (p = 0.03 and p < 0.01, respectively) sensitivity. Ki67 weak positive immunostaining was associated with topotecan (p < 0.01), gemcitabine (p < 0.01), and doxorubicin (p < 0.01) resistance. Chemosensitivity to CBDCA/PTX was associated with the ORR of neo-adjuvant (p = 0.03) and adjuvant (p = 0.02) chemotherapy. The MTT assay results of ascites were consistent with the clinical response (p = 0.04) and TTP (p = 0.04) in patients with platinum-resistant relapse EOC tumors. Conclusions: Evaluation of the chemosensitivity of ascites in EOC by MTT can aid the establishment of individualized clinical chemotherapeutic plans for platinum-resistant relapse patients.
Epithelial ovarian cancer
Drug sensitivity assay
Back to top